Vaxxinity Announces Board Appointments and Establishes New Headquarters in Florida
Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of…
Risk Management
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
Company Announcement Net sales of DARZALEX® in 2022 totaled USD 7,977 million Genmab receives royalties…
Correction to Company Announcement No. 1 of January 3, 2023
Company Announcement COPENHAGEN, Denmark; January 19, 2023 – Genmab A/S (Nasdaq: GMAB) Correction: In company…
Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions
Intrasense opens its share capital to the Guerbet Group, which announces its intent to file…
Nicox Announces Proposed Move to Euronext Growth Paris
Press Release Nicox Announces Proposed Move to Euronext Growth Paris Intention to transfer listing…
PersonalRX Earns URAC Accreditation in Mail Service Pharmacy
The Designation Demonstrates the Highest Level of Commitment to Quality Healthcare EAST RUTHERFORD, N.J., Jan….
Biogen Names Priya Singhal as Executive Vice President, Head of Development
CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced that Priya…
Genmab to Present at the 41st Annual J.P. Morgan Healthcare Conference
Media Release COPENHAGEN, Denmark; January 2, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its…
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Media Release COPENHAGEN, Denmark; December 21, 2022 JNDA submission supported by results of Japanese and…
Genmab to Hold 2022 R&D Update and ASH Data Review Meeting
Media Release Event to be held live in New Orleans, Louisiana Meeting to be webcast…
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting
Media Release COPENHAGEN, Denmark; December 11, 2022 Epcoritamab featured in multiple data disclosures, including four…
Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Media Release COPENHAGEN, Denmark; November 21, 2022 Epcoritamab BLA accepted for FDA Priority review; FDA…
Genmab to Present at Jefferies London Healthcare Conference
Media Release COPENHAGEN, Denmark; November 10, 2022 Genmab A/S (Nasdaq: GMAB) announced today that its…
Genmab Announces Financial Results for the First Nine Months of 2022
November 9, 2022 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30,…
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
Media Release Copenhagen, Denmark, November 3, 2022 Nineteen abstracts accepted, including multiple presentations on the…
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL) and Diffuse Large B-Cell Lymphoma (DLBCL)
Media Release COPENHAGEN, Denmark; October 28, 2022 Genmab has Submitted Biologics License Application (BLA) to…
CytoDyn Announces Appointment of Additional Directors with Industry Experience
Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company…
CytoDyn Announces Appointment of Additional Directors with Industry Experience
Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company…
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
Company Announcement Net sales of DARZALEX® in the third quarter of 2022 totaled USD 2,052…